Related by context. All words. (Click for frequent words.) 79 Develop Novel 75 Shows Promise 75 Receives Orphan Drug Designation 74 Jointly Develop 74 Announce License Agreement 74 FDA Clears 74 Files IND 74 Announce Collaboration 73 Receives Patent 73 Drug Candidate 73 Develop Next Generation 73 Submits Application 72 Acquires Exclusive 72 Announce Agreement 72 Announces FDA Clearance 72 Files Patent Application 72 Signs Licensing Agreement 71 Receives FDA Clearance 71 Signs Agreements 71 Present Preclinical Data 71 Achieves Milestone 71 Enters Agreement 71 Initiates Clinical Trial 71 Announces License Agreement 71 Completes Enrollment 71 Expand Collaboration 71 Enter Into 71 Announces Initiation 71 Awarded Patent 70 Initiate Clinical Trial 70 Submits NDA 70 Patent Issued 70 Receives Milestone Payment 70 Obtains License 70 Initiates Phase II 70 Completes Patient Enrollment 70 Commercialize Novel 70 Demonstrates Potential 70 Initiates Clinical 70 FDA Okays 70 Commercializes 70 Sign Licensing Agreement 70 Presents Preclinical Data 70 FDA Approves 70 Licenses Novel 69 Receives Approval 69 Monoclonal Antibody 69 Patent Covering 69 Accelerate Commercialization 69 Scientists Develop 69 Sign License Agreement 69 Significantly Increases 69 Presents Positive 69 Meets Primary Endpoint 68 Successfully Tested 68 Secures Financing 68 Enters Into Exclusive 68 Receives Approvable Letter 68 Signs License Agreement 68 Begins Shipping 68 Improves Survival 68 Significantly Improves 68 Initiates Dosing 68 Develop Innovative 68 Validates 68 Reduces Risk 68 Holds Promise 68 Initiates Phase III 68 Files Patent 68 Announce Collaboration Agreement 68 Molecular Diagnostic Test 68 Reports Preclinical Data 68 Exclusive License 68 Initiates Enrollment 68 Establish Joint Venture 68 Small Molecule 68 Novel Therapeutic 68 Extend Collaboration 68 Rheumatoid Arthritis Drug 68 Signs Pact 68 IND Application 68 Secures Funding 68 Announce Exclusive 67 Submits Biologics License Application 67 Develops Novel 67 Successfully Treated 67 Secures Additional 67 Phase 2b Clinical Trial 67 Enrolls First 67 Gets Approval 67 Milestone Payment 67 Announces Licensing Agreement 67 Study Demonstrates 67 Extends Reach 67 Enters Into Agreement 67 Phase III Clinical Trial 67 Researchers Develop 67 Signs Exclusive 67 Reports Positive 67 Study Indicates 67 Complete Merger 67 Initiates Clinical Trials 67 Preclinical Data 67 Signs Agreement 67 Pivotal Study 67 Identifies Potential 67 Announce Merger Agreement 67 Expands Portfolio 67 Clinical Trial Evaluating 67 Extends Collaboration 67 Progresses 67 Reacquires 67 Signs Distribution 67 Seeks Approval 67 Demonstrates Ability 67 Expands Distribution 67 Study Confirms 67 Generic Version 67 Gets FDA Clearance 67 Phase III Trial 66 Demonstrates Significant 66 Discontinues 66 Receives Orphan Drug 66 Vaccine Adjuvant 66 Obtains Approval 66 Announces Positive 66 Successfully Complete 66 Exercises Option 66 Ink Deal 66 Enters Into Collaboration 66 Successfully Completes Phase 66 Demonstrates Positive 66 Announce Licensing 66 Arthritis Drug 66 Prolongs Survival 66 Granted Orphan Drug 66 Announce Partnership 66 Systemic Delivery 66 FDA Accepts 66 Shows Promising 66 Reaffirms Commitment 66 Submits IND 66 Successfully Completes 66 Successfully Tests 66 AnaSpec Introduces 66 Receives Positive Opinion 66 Enters Into Strategic 66 Completes Successful 66 FDA Approvals 66 Study Identifies 66 Expand Into 66 Subsidiary Enters 66 Signs LOI 66 Researchers Identify 66 Acquire Assets 66 Signs MOU 66 Patients Treated With 66 Announce Joint Venture 66 Wins Approval 66 Collaborators Present 66 Shows Promise Against 66 Announce Licensing Agreement 66 Inhibits 66 Dramatically Increases 66 Announces Discontinuation 66 Brain Cells 66 Enters Joint Venture 66 Begin Clinical Trials 66 Fortifies 66 Announces Successful Completion 66 Multi Billion Dollar 66 Transdermal Patch 66 Drug Fails 66 Introduces Breakthrough 66 Signs Definitive Agreement 66 Announces Publication 66 Join Forces 66 Gains Momentum 66 Forms Joint Venture 66 Strengthens Its 66 Significantly Expand 66 Clinical Trial Results 66 Initiates Phase 66 Trial Evaluating 65 Could Revolutionize 65 Obtains Exclusive License 65 Expand Relationship 65 Epilepsy Drug 65 Mylan Receives Approval 65 Announce Completion 65 Signs Long Term 65 Enters Into 65 Cholesterol Lowering Drug 65 Rapidly Growing 65 Begins Shipment 65 Lung Cancer Drug 65 Significantly Improve 65 Strengthens Position 65 RNAi Therapeutics 65 Further Strengthens 65 Report Analyzes 65 Inks Pact 65 Expanded Indication 65 Proven Effective 65 Announces Termination 65 Proves Successful 65 Begins Dosing 65 Announces Expansion 65 Lupus Drug 65 Phase 2a Trial 65 Announces Presentation 65 Novel Oral 65 Revolutionize 65 Announces Issuance 65 Successfully Completed 65 Presents Preclinical 65 Announce Strategic 65 Bird Flu Vaccine 65 Drug Shows Promise 65 Closes Acquisition 65 Commences Phase 65 Single Dose 65 Announces Signing 65 Proves Effective 65 Enters Strategic 65 Tumor Targeting 65 Awarded Contract 65 Announce Receipt 65 Develops Innovative 65 Improve Survival 65 Patient Enrollment 65 Drug Resistant 65 Commercially Available 65 Pave Way 65 TB Vaccine 65 Announces Availability 65 Disease Modifying 65 Being Studied 65 Misonix Announces 65 Submits Supplemental 65 Enters Into Licensing Agreement 65 Introduces Novel 65 Announces Immediate Availability 65 Awarded Qualifying Therapeutic 65 Furthers 65 Induces 65 Announces Successful 65 Expands Availability 65 Antibody Drug Conjugate 65 Diversifies 65 Help Detect 65 Files Investigational 65 Revitalizes 65 Effectively Treats 65 BioSante Pharmaceuticals Announces 65 Cancer Cells 65 Previously Treated 65 Report Examines 65 Earns Milestone Payment 65 Acquire Controlling Interest 65 Collaborators Publish 65 Obtains Patent 65 Expand Capacity 65 Provide Comprehensive 65 Finalizes Acquisition 65 Eliminates Need 65 Interferon Alpha 65 Attains 65 Expand Presence 65 Recombinant Human 65 Flagship Product 65 Generic Versions 65 Successfully Concludes 65 Jointly Announce 65 Inks Agreement 64 Advanced Melanoma 64 Anti Tumor 64 Oral Calcitonin 64 Sign Pact 64 Help Prevent 64 Receives Order 64 Licensing Pact 64 Patents Covering 64 Osteoporosis Treatment 64 Inks Distribution 64 Cancer Treatments 64 Study Evaluating 64 Prostate Cancer Vaccine 64 PRN FDA Approves 64 Scientists Uncover 64 Suppresses 64 Investigational Compound 64 Immune Cells 64 Significantly Reduces 64 Reach Agreement 64 Scientists Identify 64 Provides Comprehensive 64 Investigational Treatment 64 Helps Prevent 64 Psoriasis Drug 64 Malaria Vaccine 64 Therapeutic Antibody 64 Achieves Primary Endpoint 64 Announces Receipt 64 Further Validates 64 Cholesterol Drug 64 Executes Agreement 64 Insights Into 64 Expands Presence 64 Help Improve 64 Recombinant Protein 64 Improves Outcomes 64 Unveils Innovative 64 Significantly Improved 64 Launches Innovative 64 Be Treated 64 Achieves Significant 64 Synthetic Peptide 64 Phase 2b Trial 64 Licensing Deal 64 Announces Launch 64 Introduces Next Generation 64 Announces Completion 64 Issued Patent 64 Test Detects 64 Receives Clearance 64 Topical Treatment 64 microRNA Therapeutics 64 Launches Next Generation 64 Protease Inhibitor 64 Study Suggests 64 STERIS Corporation Announces 64 Detect Cancer 64 Study Showed 64 Submits 64 Receives Positive 64 Formalizes 64 Biomarker Study 64 Awarded Patents 64 Phase IIb Trial 64 Is Well Tolerated 64 Launches Website 64 Tumor Cells 64 Offers Affordable 64 Protein Linked 64 Signs Contract 64 FDA Clearance 64 Announces Commencement 64 Receive Milestone Payment 64 Obtains 64 Initiate Phase III 64 Phase III Trials 64 Unveils Latest 64 Revolutionizes 64 Completes Purchase 64 Exclusive Distribution 64 Successfully Treats 64 Announces Tentative Approval 64 Avian Flu Vaccine 64 Secures Contract 63 Announce Settlement 63 Expands Capabilities 63 Phase IIa Clinical Trial 63 Immunomedics Announces 63 Signs Joint Venture 63 Anti Angiogenesis 63 Completes Merger 63 Accelerate Adoption 63 Help Predict 63 FDA Warns 63 JAK2 Inhibitor 63 Signs Letter 63 Restructures 63 Shown Effective 63 Blood Thinner 63 Reaches Milestone 63 Unveil 63 SABER ™ 63 First Patient Dosed 63 Secures 63 Markets Examine 63 Momentum Continues 63 Sign Definitive Agreement 63 Changes Name 63 Clinical Study Shows 63 Patients Suffering 63 Commence Phase 63 Expands 63 Deliver Integrated 63 Be Tested 63 Enters Negotiations 63 Launches Unique 63 Platform Enables 63 Jointly Explore 63 Forges Ahead 63 Unveils Expanded 63 Helps Predict 63 Opens Door 63 Gain Insight 63 NDA Submission 63 Introduces Revolutionary 63 Therapeutic Vaccines 63 Help Reduce 63 Gene Linked 63 Completes Initial 63 Signs Deal 63 Provides Clues 63 Completes Expansion 63 Combination Therapy 63 Subsidiary Signs 63 Voluntarily Withdraw 63 Completes Financing 63 Initiate Phase 63 Finalize Agreement 63 Deliver Innovative 63 Deliver Powerful 63 Anticancer Drug 63 Strikes Deal 63 Ink Pact 63 Provide Enhanced 63 Improve Outcomes 63 Accelerate Growth 63 Patients Treated 63 Humanized Anti 63 Exclusive Distributor 63 Provides Update Regarding 63 Osteoporosis Drug 63 Novel Treatments 63 Settle Patent Litigation 63 Expands Scope 63 Treatment Experienced 63 BioElectronics Announces 63 Be Showcased 63 Long Lasting 63 Gene Mutation 63 siRNA Delivery 63 Tumor Growth 63 Makes Headway 63 Kinase Inhibitor 63 Can Detect 63 Novel Antibiotic 63 Bolsters 63 Being Tested 63 Unveils Next Generation 63 Reveals Positive 63 Receives Tentative Approval 63 Phase IIb Clinical Trial 63 Significantly Reduce 63 Receives Funding 63 Acquires Assets 63 Announces Expanded 63 Entry Into 63 Amplifies 63 Remains Committed 63 Expands Reach 63 Announces Filing 63 Announces Formation 63 Accelerates 63 Oral Formulation 63 Be Studied 63 Announces Addition 63 Therapeutic Competitors Companies 63 Widely Used 63 Closes Financing 63 Largest Ever 63 Announces Acquisition 63 Extend Partnership 63 Proudly Announces 63 Dramatically Reduce 63 Inks Deal 63 First Patient Enrolled 63 Nerve Cells 63 Launches 63 Accelerates Growth 63 Reinforces 63 Deliver Enhanced 63 Pursues 63 Aligns 62 Pharmaceuticals Initiates 62 Metastatic Melanoma 62 Mouse Model 62 Inhaled Corticosteroids 62 Improve Efficiency 62 Companion Diagnostic 62 Slow Progression 62 Announce Initiation 62 Rolls Out 62 Novel Compounds 62 CysDisplay R 62 Diagnostic Tests 62 Genes Linked 62 Obtains Exclusive Rights 62 Vascular Inflammation 62 Reconfirms 62 Inks Deals 62 Expands Into 62 Presents Positive Preclinical 62 Protein Biomarkers 62 Enters Into Joint Venture 62 Jointly Offer 62 Novel Compound 62 Beneficial Effects 62 Drug Combo 62 Panel Backs 62 Signs Option Agreement 62 Shows Statistically Significant 62 Smallpox Vaccine 62 Anti Tumor Activity 62 Introduces Innovative 62 Reaches Agreement 62 Nanofiber 62 Rotavirus Vaccine 62 Receives SFDA Approval 62 Adjuvant Treatment 62 Genes Associated 62 Voluntarily Withdraws 62 ADDING MULTIMEDIA 62 Tuberculosis Vaccine 62 Nicotine Vaccine 62 Receives Commitment 62 Improve Quality 62 Preclinical Study 62 Report Identifies 62 Significantly Enhances 62 Approve Merger 62 Procures 62 Subsidiary Enters Into 62 Outstrip 62 Study Examines 62 Mutually Agree 62 COMUNICADO 62 Announce Availability 62 Paves Way 62 Receives Conditional 62 Biotech Firm 62 Unlock Secrets 62 Spur Growth 62 Announces Intent 62 Amends Agreement 62 Subsidiary Receives 62 Advanced Colorectal Cancer 62 Obtains FDA 62 Secures Long Term 62 Receives Notice 62 Stem Cell Treatment 62 Finalizes 62 Announce Formation 62 News Unternehmensnachrichten 62 First Patient Treated 62 Unlocks 62 Strengthen Ties 62 Vaccine Candidate 62 Offers Unique 62 Expands Capacity 62 Reduce Costs 62 Clears Path 62 Gets Boost 62 Provides Guidance 62 Enrolling Patients 62 Affirms Commitment 62 Inks Licensing Deal 62 Cancer Vaccine 62 Deliver Next Generation 62 Continues Momentum 62 Skin Cells 62 Provides Updates 62 Terminate Merger Agreement 62 Develops Next Generation 62 Contrast Agent 62 Lowers Risk 62 Hsp# Inhibitor 62 Announces Definitive Agreement 62 Microfluidic Devices 62 Announce Intention 62 Completes Dosing 62 Submits Response 62 Wins Contract 62 Broadens 62 Less Invasive 62 Announce Definitive Agreement 62 Confirms Commitment 62 Study Proves 62 Effective Than 62 Enters Into License Agreement 62 Expedites 62 Receives Complete Response 62 Predict Dementia 62 Cervical Cancer Vaccine 62 Schizophrenia Drug 62 Signs Definitive Agreements 62 Moves Forward 62 Demonstrated Significant 62 Ultra Sensitive 62 Seasonal Influenza Vaccine 62 Reduces Pain 62 Boost Efficiency 62 FDA Approves Generic 62 Severe Sepsis 62 RNAi Therapeutic 62 Strengthens Balance Sheet 62 Taro Receives 62 Pushes Ahead 62 Strengthens Commitment 62 Artificial Skin 62 Completes Sale 62 INDUSTRY ASSESSMENTS 62 Antitumor Activity 62 Delivers Next Generation 62 Completes Reverse Merger 62 platform HDL Mimetic 62 Cocaine Addiction 62 Terminates Agreement 62 Antibiotic Resistant 62 Outperforms 62 Provides Detailed 62 Fast Track Status 62 Molecular Diagnostic 62 Newly Identified 62 Study Shows 62 Acquires 62 Rheumatoid Arthritis Patients 62 JAK Inhibitor 62 Anticancer Agent 62 Nears Completion 62 Joins Forces 62 Experts Urge 61 Prolongs 61 Spins Out 61 Completes Installation 61 Debuts 61 Receives Certification 61 Penetrate 61 Broadens Its 61 Ebola Vaccine 61 Expands Internationally 61 Finalizes Agreement 61 Well Tolerated 61 Protects Against 61 Protein Synthesis 61 Magnetic Nanoparticles 61 Prove Effective 61 Data Suggest 61 Collaborate 61 Dry Powder Inhaler 61 Unveils 61 Gaining Momentum 61 Combination Treatment 61 Immune Cell 61 Opens Doors 61 Could Detect 61 Testosterone Gel 61 Rapidly Expanding 61 Penetrates 61 Establishes Strategic 61 Initiates Phase 2b 61 Completes Acquisition 61 Rebrands 61 Antisense Drug 61 Receives Confirmation 61 Terminates Contract 61 Demonstrates Improved 61 Novel Protein 61 Settles Litigation 61 Fixed Dose Combination 61 Moves Ahead 61 Commences Production 61 License Pact 61 Gain Traction 61 Blood Pressure Drug 61 Significantly Reduced 61 Chronic Hepatitis B 61 Enhances 61 Results Confirm 61 Clinical Study 61 Announce Commencement 61 Collaborates With 61 Energizes 61 Announces Divestiture 61 Announces Sponsorship 61 Migraine Drug 61 Solidifies 61 Demonstrates Commitment 61 Adjunctive Therapy 61 Aptamer 61 Cholesterol Drugs 61 Files Shelf Registration Statement 61 Receives CE 61 Bush Embraces Pause 61 Distribution Pact 61 Doubles Size 61 Launches Generic Version 61 Gene Variant 61 Unveils Revolutionary 61 Demonstrates Potent 61 Appears Safe 61 Submits Proposal 61 Non Invasive 61 Announces 61 Antifungal 61 Announces Preliminary 61 Patent Broadly Covering 61 Helps Improve 61 Collaborates 61 Teva Provides Update 61 Announce 61 Boehringer Ingelheim MedImmune 61 FDA APPROVES 61 Evolves 61 Ligands 61 Pinpointed 61 Reduce Risk 61 Receives Approval From 61 Treatment Reduces 61 Strengthens Leadership 61 Effort Needed 61 Announces Intention 61 Identifies Key 61 Forms Strategic 61 Fully Automated 61 Spins Off 61 Solution Enables 61 Avian Influenza Vaccine 61 Patients Enrolled 61 ANADIGICS Announces 61 Successfully Closes 61 Acquires Controlling Interest 61 Be Cured 61 Taps Into 61 Moves Towards 61 Resubmits 61 Study Reinforces 61 Builds Momentum 61 Patent Infringement Lawsuit Against 61 Announce Expanded 61 Receives CE Marking 61 Exclusive Licensing Agreement 61 k Clearance 61 Makes Strides 61 Move Closer 61 Continues Expansion 61 Could Prevent 61 Explore Strategic Alternatives 61 High Growth Forecasted 61 Helps Identify 61 Showcases Innovative 61 Expansion Into 61 Study Casts Doubt 61 Establishes Joint Venture 61 Announces Stockholder Approval 61 Shows Efficacy 61 Prostate Cancer Patients 61 Latest Addition 61 Cypher Sirolimus 61 Study Links 61 Nanoemulsion 61 Announce Breakthrough 61 Stimulates 61 Increased Risk 61 Break Ground 61 Unveils Groundbreaking 61 Gains Traction 61 Files Patents 61 Completes Merger With 61 Licenses Patents 61 Increase Efficiency 61 Dedicates 61 Introduces 61 Announce Launch 61 Enters Exclusive 61 Mobilizes 61 Step Closer 61 Significant Increase 61 Momentum Grows 61 Leadership Position 61 Extend Reach 61 Cholesterol Lowering 61 Receives Regulatory 61 Increases Risk 61 Inks Licensing Agreement 61 Gold Nanorods 61 Study Concludes 61 Gout Drug 61 Study Uncovers 61 Signs Licensing 61 Obtains Exclusive 61 Renews Agreement 61 Strengthens Presence 61 Reportlinker Adds 61 Repositions 61 Positive Results 61 Bioresorbable 61 Inks Deal With 61 Significantly Expands 61 Remain Competitive 61 Blood Clotting 61 Novel Vaccine 61 Forges Strategic 61 Offers Unprecedented 61 Demonstrates Efficacy 61 Patents Issued 61 Helps Reduce 61 Achieves Record Sales 61 Sagent Pharmaceuticals Announces 61 Consummates 61 Pivotal Trials 61 Play Crucial Role 61 Expand Coverage 61 Relapsed Refractory 61 Commonly Used 61 Outpace 61 Receives Approvals 61 Treatment Naïve 61 Study Sheds Light 61 Nucleoside 61 Sustains 61 Reinvents 61 Distinguishes 61 FDA Approves Drug 61 Receives Fast Track 61 Forges Partnership 61 Outlines Strategy 61 Plays Role 60 Launches Enhanced 60 Resolve Dispute 60 Market Penetration 60 Acquire Stake 60 Certifies 60 Commences Operations 60 Grants Awarded 60 Personalized Immunotherapy 60 Investigational Drug 60 Prolongs Life 60 Randomized Trials 60 Jointly Promote 60 Recall Issued 60 Finalizes Purchase 60 Launches Groundbreaking 60 & Sullivan Recognizes 60 Immune Responses 60 Concludes Successful 60 Boosts Productivity 60 Immunotherapeutic 60 Inks License 60 Gets Nod 60 Antiviral Drugs 60 Protein Expression 60 Shareholders Approve Merger 60 Targeted Therapies 60 Receives Recognition 60 Introduces Unique 60 Improves Quality 60 Lanthanum Carbonate 60 Expert Discusses 60 Announce Signing 60 Releases Next Generation 60 Patent Dispute 60 Nasopharyngeal Electrodes Needle Electrodes 60 Treat Heart Failure 60 Demonstrates Statistically Significant 60 Leading Provider 60 Previously Untreated 60 Board Authorizes 60 Breast Cancer Recurrence 60 Announce Merger 60 Mouse Models 60 Previously Announced 60 Imaging Technique 60 Blood Vessels 60 Restructures Debt 60 Achieve Significant 60 Oral Insulin 60 Gain Momentum 60 Findings Suggest 60 Fat Cells 60 Announces Enhancements 60 Completes Tender Offer 60 NEC Develops 60 Therapeutic Vaccine 60 Completes Transition 60 Regenerative Cells 60 Demonstrates Long Term 60 Receptor Agonist 60 HuCAL PLATINUM R 60 Gains Ground 60 Technological Advances 60 Rolled Out 60 Insulin Resistance 60 Embryonic Stem Cells 60 Website Launched 60 Viable Alternative 60 Treating Chronic 60 Be Evaluated 60 Signs Merger Agreement 60 Cites Positive 60 Signs Memorandum 60 Replacement Therapy 60 STRATEGY ANALYTICS 60 Inks Exclusive 60 Novel Antibody 60 Oral Interferon 60 Brain Metastases 60 Impairs 60 HER2 Positive 60 Breast Cancer Cells 60 Introduces Enhanced 60 Therapeutic Efficacy 60 Refocuses 60 Takes Steps 60 Being Evaluated 60 Unifies 60 Reach Settlement 60 Generic Version Of 60 Appoints Seasoned 60 Updates Status 60 Relaunches 60 Receives Favorable 60 Prevent Spread 60 ORLive Presents 60 Halts Production 60 Build Momentum 60 Confirms Efficacy 60 Newly Released 60 Oral Mucositis 60 Help Ease 60 Extend Relationship 60 Achieves Highest 60 Commences 60 Sustain Growth 60 Withdraws Application 60 Product Offerings 60 Differentiates 60 Expands Offerings 60 Phase 1b Clinical Trial 60 Successful Launch 60 GRAS Status 60 Streamlines Operations 60 Attenuates 60 Acquire Privately Held 60 Announce Expiration 60 Genentech GlaxoSmithKline 60 Redefines 60 Biosynthetic 60 Spectrum Pharmaceuticals Announces 60 Asthma Treatment 60 Study Validates 60 Low Dose 60 Strategic Relationship 60 Carbon Nanotube 60 Investigational Agent 60 Demonstrates 60 Step Toward 60 Deliver Comprehensive 60 TRANSDUR ™ 60 Terminates 60 Expands Coverage 60 Reorganizes 60 Delivers Enhanced 60 Commences Phase III 60 Files Registration Statement 60 Successful Completion 60 Prophylactic Treatment 60 Help Solve 60 Study Compares 60 Combination REOLYSIN R 60 Reaches Pact 60 Survival Benefit 60 Annouces 60 Potentially Fatal 60 Tyrosine Kinase Inhibitor 60 Phase 2b Study 60 Protein Biomarker 60 VIVUS Announces 60 Secures Exclusive 60 Restructures Operations 60 Initiates 60 Secures Patent 60 Raise Awareness 60 Achieves Breakthrough 60 Raise Awareness About 60 Atopic Dermatitis 60 Settle Dispute 60 Aloxi ® 60 Protect Against 60 Testing Capabilities 60 Moves Closer 60 Exploit collaboration 60 Regains Compliance 60 Phase IIa Trial 60 Gives Clues 60 HER2 Positive Breast Cancer 60 Momentum Builds 60 Achieves Milestones 60 Reduce Carbon Emissions 60 Distribution Agreements 60 Xcytrin R 60 Complicated Skin 60 Could Save Lives 60 Reactivates 60 Elevates